Skip to main content
ALGORAE PHARMACEUTICALS LIMITED logo

ALGORAE PHARMACEUTICALS LIMITED — Investor Relations & Filings

Ticker · 1AI ISIN · AU0000296022 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,159 across all filing types
Latest filing 2011-11-27 Investor Presentation
Country AU Australia
Listing ASX 1AI

About ALGORAE PHARMACEUTICALS LIMITED

https://algoraepharma.com/

Algorae Pharmaceuticals Limited is a biopharmaceutical company focused on the discovery and development of novel therapeutic solutions for complex medical conditions. The company leverages its proprietary artificial intelligence platform, AlgoraeOS, to streamline the drug discovery process and identify synergistic drug combinations. Its research pipeline primarily targets neurodegenerative diseases and other areas of high unmet clinical need. Key development programs include AI-116, a combination therapy aimed at treating dementia and Alzheimer's disease. By integrating advanced computational modeling with traditional pharmacological research, the company seeks to accelerate the transition of candidates from preclinical stages to clinical trials, optimizing therapeutic efficacy and safety profiles.

Recent filings

Filing Released Lang Actions
CEO`s Presentation to the 2011 AGM 6 pages 150.9KB
Investor Presentation Classification · 95% confidence The document is a detailed presentation discussing the company's business developments, future product pipeline, clinical trials, and strategic partnerships. It includes descriptions of R&D activities, product development timelines, and introductions of senior managers involved in the research. The content is forward-looking and strategic, focusing on explaining the company's current status and future plans to an audience, likely investors or analysts. There are no financial statements, quarterly or annual results, nor is there a formal report or regulatory filing referenced as attached or published. The document resembles an investor presentation rather than a formal report or announcement. Therefore, the most appropriate classification is Investor Presentation (IP).
2011-11-27 English
Results of the 2011 Annual General Meeting 5 pages 79.5KB
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is titled 'Results of the Annual General Meeting held on 28 November 2011' and contains detailed voting results for multiple resolutions presented at the AGM, including adoption of the remuneration report, election and re-election of directors, ratification of share issues, and approval of options issuance. The content focuses on the official announcement of shareholder voting outcomes at the AGM. There is no detailed financial data, management discussion, or full report content, but rather the formal disclosure of voting results as required by regulatory rules (Listing Rule 3.13.2 and Corporations Act section 251AA (2)). This matches the definition of 'Declaration of Voting Results & Voting Rights Announcements (DVA)'. The document length is sufficient and the content is substantive for this category, not a mere announcement of a report or a proxy solicitation. Therefore, the correct classification is DVA with high confidence.
2011-11-27 English
Change of Director`s Interest Notice 2 pages 97.2KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and references ASX listing rule 3.19A.2 and section 205G of the Corporations Act. It details a change in a director's relevant interests in securities, including the number of shares held before and after the change, the nature of the change (on-market trade), and dates. This type of document is a formal notification of personal share transactions by a company director. It does not contain financial performance data, management discussion, or other report content. Therefore, it fits the definition of 'Director's Dealing' filings, which report personal share transactions by company directors and executives (insider trades). The document length is 4288 characters, which is consistent with a detailed notice rather than a full report or announcement. Hence, the correct classification is DIRS with high confidence.
2011-11-23 English
Change of Director`s Interest Notice 2 pages 88.3KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and references ASX listing rules and the Corporations Act. It details a director's change in shareholding, including the number of shares held before and after the transaction, the nature of the transaction (on-market trade), and dates. This matches the definition of a Director's Dealing report, which reports personal share transactions by company directors and executives. The document length is 3447 characters, which is consistent with a detailed notice rather than a brief announcement. There is no indication that this is an annual report, earnings release, or any other type of filing. Therefore, the correct classification is Director's Dealing (DIRS).
2011-11-17 English
Change of Director`s Interest Notice 2 pages 89.6KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and references ASX listing rule 3.19A.2 and section 205G of the Corporations Act. It details a director's change in shareholding, including the number of shares held before and after the transaction, the date of change, and the nature of the transaction (on-market trade). The document is a formal notification of a director's personal share transactions. It does not contain financial statements, management discussion, or other report content. This matches the definition of 'Director's Dealing' filings, which report personal share transactions by company directors and executives (insider trades). The document length is 3341 characters, consistent with a short notice rather than a full report. Therefore, the correct classification is DIRS (Director's Dealing).
2011-11-03 English
Settlement of $A50 million JV to commercialise DIABECELL 2 pages 89.4KB
Capital/Financing Update Classification · 95% confidence The document is a company announcement from Living Cell Technologies Limited regarding the settlement of a $A50 million joint venture to commercialize a product called DIABECELL. It details the transaction completion, asset transfers, and strategic collaboration with Otsuka Pharmaceutical Factory. The content is focused on a specific financing and partnership update rather than a full financial report, earnings release, or regulatory filing. There are no financial statements or detailed financial performance data included. The document is about a capital transaction and joint venture settlement, which fits the category of Capital/Financing Update (CAP). The document length is 6977 characters, which is sufficient for a detailed announcement but does not constitute a full report like an annual or interim report. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2011-11-01 English

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.